$BRVE News

Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Braveheart Bio Q2 EPS $(2.51)

Braveheart Bio to Participate in Cantor Global Healthcare Conference

Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48

TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating

Jefferies Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48

Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40

Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45

Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Braveheart Bio IPO Indicating $25.50/Share On 310K Shares; IPO Priced At $18/Share

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

Braveheart Bio Readies $300 Million IPO Plan